{"url_path":"/sec/btcy/10-k/2026/item-11","section_key":"item-11","section_title":"Item 11 EXECUTIVE COMPENSATION**","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-07-14","source_url":"https://www.sec.gov/Archives/edgar/data/1630113/0001493152-26-033207-index.html","accession_number":"0001493152-26-033207","cik":"0001630113","ticker":"BTCY","issuer_name":"BIOTRICITY INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1630113/0001493152-26-033207-index.html","primary_entity_key":"0001630113","primary_entity_name":"BIOTRICITY INC."},"word_count":1257,"has_tables":true,"body_markdown":"**ITEM\n11. EXECUTIVE COMPENSATION**\n\n \n\nThe\nfollowing table set forth certain information as to the compensation paid to the executive officers of the Company and iMedical, its\npredecessor, for the fiscal years ended March 31, 2026 and March 31, 2025.\n\n \n\n**Name and**\n\n**Principal Position**\n\n \n**Fiscal Year**\n \n \n**Salary**\n \n \n**Bonus**\n \n \n**Stock Awards**\n \n \n**Option/Warrant Awards(1)**\n \n \n\n**Non-Equity Incentive Plan**\n\n**Compensation**\n\n \n \n**All Other Compensation**\n \n \n**Total**\n \n\n**Waqaas Al-Siddiq**\n \n \n2026\n \n \n$\n480,000\n \n \n$\n240,000\n \n \n \n \n \n \n$\n-\n \n \n \n \n \n \n$\n12,000\n \n \n$\n732,000\n \n\nChief Executive Officer\n \n \n2025\n \n \n$\n480,000\n \n \n$\n240,000\n \n \n \n \n \n \n$\n275,596\n \n \n \n \n \n \n$\n12,000\n \n \n$\n1,007,596\n \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n**John Ayanoglou**\n \n \n2026\n \n \n$\n300,000\n \n \n$\n250,000\n \n \n \n \n \n \n \n-\n \n \n \n \n \n \n$\n12,000\n \n \n$\n562,000\n \n\nChief Financial Officer\n \n \n2025\n \n \n$\n300,000\n \n \n$\n250,000\n \n \n \n \n \n \n \n176,023\n \n \n \n \n \n \n$\n12,000\n \n \n$\n738,023\n \n\n \n\n \n\n \n(1)\nFor\nfurther disclosure, as well as assumptions made in such valuation, see Note 9 to our audited financial statements included in this\nAnnual report on Form 10-K, commencing on page F-1. Amounts shown as Option awards for Waqaas al Siddiq are due to cancellation and\nreissuance of options. Amounts shown as option awards for Mr. Ayanoglou were granted as warrants, while he was not a member of the\nCompany’s options plans.\n\n** **\n\n**Outstanding\nEquity Awards at Fiscal Year-End**\n\n \n\nThe\nfollowing table provides information about the number of outstanding equity awards held by our named executive officers at March 31,\n2026:\n\n \n\n \n \n \n \n \n \n \n \n \n \n \n**Option\nAwards(1)**\n \n \n \n \n \n\n**Name**\n \n**Award\nType**\n \n**Grant Date**\n \n \n**Number\nof\nsecurities\nunderlying\nunexercised\noptions or\nwarrants\nexercisable**\n \n \n**Number\nof\nsecurities\nunderlying\nunexercised\noptions or\nwarrants\nexercisable**\n \n \n**Option\nor\nWarrant\nexercise\nprice\n($)**\n \n \n \n**Option\nor\nWarrant\nexpiration\ndate**\n \n\nWaqaas\nAl-Siddiq\n \nOption\n \n \n7-25-24\n \n \n \n250,000\n (1)\n \n \n \n \n \n$\n1.20\n \n \n \n7-25-34\n \n\nWaqaas\nAl-Siddiq\n \nOption\n \n \n2-14-25\n \n \n \n900,000\n (1,2)\n \n \n                \n \n \n$\n0.43\n \n \n \n2-14-35\n \n\nJohn\nAyanoglou\n \nWarrant\n \n \n10-26-17\n \n \n \n8,333\n (2,3)\n \n \n \n \n \n$\n0.43\n \n \n \n12-31-30\n \n\nJohn\nAyanoglou\n \nWarrant\n \n \n3-31-18\n \n \n \n8,333\n (2,3)\n \n \n \n \n \n$\n0.43\n \n \n \n12-31-30\n \n\nJohn\nAyanoglou\n \nWarrant\n \n \n6-30-18\n \n \n \n8,333\n (2,3)\n \n \n \n \n \n$\n0.43\n \n \n \n12-31-30\n \n\nJohn\nAyanoglou\n \nWarrant\n \n \n9-30-18\n \n \n \n8,333\n (2,3)\n \n \n \n \n \n$\n0.43\n \n \n \n12-31-30\n \n\nJohn\nAyanoglou\n \nWarrant\n \n \n12-31-18\n \n \n \n8,333\n (2,3)\n \n \n \n \n \n$\n0.43\n \n \n \n12-30-28\n \n\nJohn\nAyanoglou\n \nWarrant\n \n \n3-31-19\n \n \n \n8,333\n (2,3)\n \n \n \n \n \n$\n0.43\n \n \n \n3-30-29\n \n\nJohn\nAyanoglou\n \nWarrant\n \n \n6-30-19\n \n \n \n8,333\n (2,3)\n \n \n \n \n \n$\n0.43\n \n \n \n6-29-29\n \n\nJohn\nAyanoglou\n \nWarrant\n \n \n9-30-19\n \n \n \n8,333\n (2,3)\n \n \n \n \n \n$\n0.43\n \n \n \n9-29-29\n \n\nJohn\nAyanoglou\n \nWarrant\n \n \n12-31-19\n \n \n \n8,333\n (2,3)\n \n \n \n \n \n$\n0.43\n \n \n \n12-30-29\n \n\nJohn\nAyanoglou\n \nWarrant\n \n \n3-31-20\n \n \n \n8,333\n (2,3)\n \n \n \n \n \n$\n0.43\n \n \n \n3-31-30\n \n\nJohn\nAyanoglou\n \nWarrant\n \n \n6-30-20\n \n \n \n8,333\n (2,3)\n \n \n \n \n \n$\n0.43\n \n \n \n6-30-30\n \n\nJohn\nAyanoglou\n \nWarrant\n \n \n9-30-20\n \n \n \n8,333\n (2,3)\n \n \n \n \n \n$\n0.43\n \n \n \n9-30-30\n \n\nJohn\nAyanoglou\n \nWarrant\n \n \n1-24-20\n \n \n \n8,333\n (2,3)\n \n \n \n \n \n$\n0.43\n \n \n \n1-23-30\n \n\nJohn\nAyanoglou\n \nWarrant\n \n \n12-31-20\n \n \n \n8,333\n (2,3)\n \n \n \n \n \n$\n0.43\n \n \n \n12-31-30\n \n\nJohn\nAyanoglou\n \nWarrant\n \n \n3-31-21\n \n \n \n8,333\n (2,3)\n \n \n \n \n \n$\n0.43\n \n \n \n3-31-31\n \n\nJohn\nAyanoglou\n \nWarrant\n \n \n4-30-17\n \n \n \n1,250\n (2,3)\n \n \n \n \n \n$\n0.43\n \n \n \n12-31-30\n \n\nJohn\nAyanoglou\n \nWarrant\n \n \n5-31-17\n \n \n \n1,250\n (2,3)\n \n \n \n \n \n$\n0.43\n \n \n \n12-31-30\n \n\nJohn\nAyanoglou\n \nWarrant\n \n \n6-30-17\n \n \n \n1,250\n (2,3)\n \n \n \n \n \n$\n0.43\n \n \n \n12-31-30\n \n\nJohn\nAyanoglou\n \nWarrant\n \n \n7-31-17\n \n \n \n1,250\n (2,3)\n \n \n \n \n \n$\n0.43\n \n \n \n12-31-30\n \n\nJohn\nAyanoglou\n \nWarrant\n \n \n8-31-17\n \n \n \n1,250\n (2,3)\n \n \n \n \n \n$\n0.43\n \n \n \n12-31-30\n \n\nJohn\nAyanoglou\n \nWarrant\n \n \n9-30-17\n \n \n \n2,917\n (2,3)\n \n \n \n \n \n$\n0.43\n \n \n \n12-31-30\n \n\nJohn\nAyanoglou\n \nWarrant\n \n \n9-30-17\n \n \n \n3,333\n (2,3)\n \n \n \n \n \n$\n0.43\n \n \n \n12-31-30\n \n\nJohn\nAyanoglou\n \nWarrant\n \n \n12-5-17\n \n \n \n2,301\n (2,3)\n \n \n \n \n \n$\n0.43\n \n \n \n12-31-30\n \n\nJohn\nAyanoglou\n \nWarrant\n \n \n6-30-21\n \n \n \n8,333\n (2,3)\n \n \n \n \n \n$\n0.43\n \n \n \n6-30-31\n \n\nJohn\nAyanoglou\n \nWarrant\n \n \n9-30-21\n \n \n \n8,333\n (2,3)\n \n \n \n \n \n$\n0.43\n \n \n \n9-30-31\n \n\nJohn\nAyanoglou\n \nWarrant\n \n \n12-31-21\n \n \n \n8,333\n (2,3)\n \n \n \n \n \n$\n0.43\n \n \n \n12-31-31\n \n\nJohn\nAyanoglou\n \nWarrant\n \n \n3-31-22\n \n \n \n6,266\n (2,3)\n \n \n \n \n \n$\n0.43\n \n \n \n3-31-32\n \n\nJohn\nAyanoglou\n \nWarrant\n \n \n6-30-22\n \n \n \n8,971\n (2,3)\n \n \n \n \n \n$\n0.43\n \n \n \n6-30-32\n \n\nJohn\nAyanoglou\n \nWarrant\n \n \n9-30-22\n \n \n \n19,714\n (2,3)\n \n \n \n \n \n$\n0.43\n \n \n \n9-30-32\n \n\nJohn\nAyanoglou\n \nWarrant\n \n \n12-31-22\n \n \n \n36,464\n (2,3)\n \n \n \n \n \n$\n0.43\n \n \n \n12-30-32\n \n\nJohn\nAyanoglou\n \nWarrant\n \n \n02-14-25\n \n \n \n500,000\n (2)\n \n \n \n \n \n$\n0.43\n \n \n \n02-14-35\n \n\n \n\n(1)\nUnless\notherwise indicated, vesting of all options is subject to continued service on the applicable vesting date.\n\n(2)\nThe\nrespective options and warrants, as applicable, vested in full upon the date of grant.\n\n(3)\nThe\nshares were repriced from original issuance date price to $0.43 on February 14, 2025.\n\n \n\n57\n\n \n\n \n\n**Employment\nAgreements**\n\n \n\n**Waqaas\nAl-Siddiq**\n\n \n\nWe entered into an employment agreement with Waqaas\nAl-Siddiq effective April 10, 2020, pursuant to which Mr. Al-Siddiq continues to serve as our Chief Executive Officer. The agreement has\nan initial term of one year and automatically renews for successive one-year periods unless either party provides at least 30 days’ prior\nwritten notice of non-renewal.\n\n \n\nUnder the agreement, Mr. Al-Siddiq\nis entitled to an annual base salary as determined by the Board of Directors. For the years ended March 31, 2026 and 2025, Mr. Al-Siddiq’s\nannual base salary was $480,000. In addition, he is eligible to receive an annual cash and/or equity bonus of up to 50% of his base salary,\nas determined by the Board of Directors.\n\n \n\nIf Mr. Al-Siddiq’s employment is terminated without\ncause or if he resigns for good reason (as defined in the employment agreement), he is entitled to receive severance equal to twelve months\nof base salary, payable in accordance with the terms of the agreement, together with any accrued but unused vacation benefits.\n\n \n\nMr. Al-Siddiq also participates in the Company’s equity\nincentive programs and may receive stock option or other equity awards from time to time. Information regarding outstanding equity awards\nis disclosed in Note 9 to the consolidated financial statements included in this Annual Report on Form 10-K.\n\n \n\nThe foregoing summary is qualified\nin its entirety by reference to the employment agreement, which was filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K\nfiled on April 13, 2020.\n\n \n\n**John\nAyanoglou**\n\n \n\nIn connection with his appointment as Chief Financial\nOfficer effective October 27, 2017, the Company entered into an employment arrangement with Mr. Ayanoglou pursuant to which he is entitled\nto receive an annual base salary, subject to adjustment by the Board of Directors, and may be eligible for cash and/or equity incentive\ncompensation.\n\nFor each of the calendar years 2022 through 2026,\nMr. Ayanoglou’s annual base salary was $300,000.\n\n \n\nIn addition, Mr. Ayanoglou is eligible to receive\nwarrants to purchase shares of the Company’s common stock. Such warrants are granted in quarterly installments and vest monthly on a pro\nrata basis over a twelve-month period. The warrants have a ten-year term and generally contain terms and conditions substantially consistent\nwith equity awards granted under the Company’s 2016 and 2023 Equity Incentive Plans.\n\n \n\nInformation regarding Mr. Ayanoglou’s outstanding\nequity awards is disclosed in Note 9 to the consolidated financial statements included in this Annual Report on Form 10-K.\n\n \n\nThe foregoing summary is qualified in its entirety\nby reference to the underlying employment arrangements and equity award agreements.\n\n \n\n**Director\nCompensation**\n\n \n\nThe\nfollowing table sets forth a summary of the compensation for our non-employee directors during the fiscal years ended March 31, 2026\nand March 31, 2025.\n\n \n\n**Name**\n \n**Year**\n \n \n**Fees Earned or Paid in Cash**\n \n \n**Stock Awards**\n \n \n**Option Awards**\n \n \n**Non-Equity Incentive Plan Compensation**\n \n \n**Nonqualified Deferred Compensation Earnings**\n \n \n**All Other Compensation**\n \n \n**Total**\n \n\n**Ronald McClurg (1)**\n \n \n2026\n \n \n$\n16,000\n \n \n \n-\n \n \n \n-\n \n \n \n-\n \n \n \n-\n \n \n \n-\n \n \n$\n16,000\n \n\n \n \n \n2025\n \n \n$\n16,000\n \n \n \n-\n \n \n \n8,801\n \n \n \n-\n \n \n \n-\n \n \n \n-\n \n \n$\n24,801\n \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n**David A. Rosa (2)**\n \n \n2026\n \n \n$\n60,000\n \n \n \n-\n \n \n \n-\n \n \n \n-\n \n \n \n-\n \n \n \n-\n \n \n$\n60,000\n \n\n \n \n \n2025\n \n \n$\n60,000\n \n \n \n \n \n \n \n44,006\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n$\n104,006\n \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n**Jainal Bhuiyan (3)**\n \n \n2026\n \n \n$\n60,000\n \n \n \n-\n \n \n \n-\n \n \n \n-\n \n \n \n-\n \n \n \n-\n \n \n$\n60,000\n \n\n \n \n \n2025\n \n \n$\n \n \n \n \n \n \n \n \n44,006\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n44,006\n \n\n \n\n(1)\nMr.\nMcClurg was appointed to the board on May 2, 2022. In addition to previous grants, on February 14, 2025, Mr. McClurg was awarded\na grant of 25,000 options, that vested on grant, and have a 10-year term, and an exercise price of $0.43.\n\n(2)\nOn\nFebruary 14, 2025, in addition to previous grants, Mr. Rosa was awarded a grant of 125,000 options, that vested on grant, and have\na 10-year term, and an exercise price of $0.43.\n\n(3)\nMr.\nBhuiyan was appointed to the board on August 15, 2024. On February 14, 2025, Mr. Bhuiyan was awarded a grant of 125,000 options,\nthat vested on grant, and have a 10-year term, and an exercise price of $0.43.\n\n \n\n58"}